100
Participants
Start Date
November 21, 2018
Primary Completion Date
August 11, 2020
Study Completion Date
August 21, 2020
Therapy
Non-directive therapy performed by therapist team
midomafetamine HCl
Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively, during three experimental sessions
Placebo
Administration of placebo during three experimental sessions
New York University, New York
New York Private Practice, New York
Zen Therapeutic Solutions, LLC, Mt. Pleasant
University of Wisconsin at Madison, Madison
Ray Worthy Psychiatry LLC, New Orleans
Aguazul-Blue Water Inc., Boulder
Wholeness Center, Fort Collins
New School Research LLT, North Hollywood
San Francisco Insight and Integration Center, San Francisco
University of California San Francisco, San Francisco
Trauma Research Foundation, Boston
Providence Health Center, Vancouver
Dr. Simon Amar, Inc., Montreal
Assaf Harofeh Research Fund, Be’er Ya‘aqov
Sheba Fund for Health Services and Research, Tel Litwinsky
Lead Sponsor
Lykos Therapeutics
INDUSTRY